Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
First Claim
Patent Images
1. ) A method of treating, stabilizing and/or preventing a complement-mediated ocular disorder, the method comprising the step of administering a therapeutically effective amount of an anti-complement aptamer to a subject in need thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject'"'"'s complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.
-
Citations
88 Claims
- 1. ) A method of treating, stabilizing and/or preventing a complement-mediated ocular disorder, the method comprising the step of administering a therapeutically effective amount of an anti-complement aptamer to a subject in need thereof.
-
3_-6. )-6) (canceled)
- 7. ) A method of stabilizing a complement-mediated ocular neovascularization disorder comprising administering an anti-complement aptamer to a subject in need thereof in an amount sufficient to stabilize the complement-mediated ocular neovascularization disorder.
-
9_-11. )-11) (canceled)
-
16_-20. )-20) (canceled)
- 21. ) A method of preventing a clinical complement-mediated ocular neovascularization disorder in a subject comprising administering an anti-complement aptamer to a subject in need thereof, in an amount sufficient to prevent a clinical symptom of the complement-mediated ocular neovascularization disorder.
-
23_-25. )-25) (canceled)
-
32_-33. )-33) (canceled)
-
38. ) The method of claim 32, wherein the C5 binding aptamer is ARC186, ARC187, ARC1905.
-
40_-41. )-41) (canceled)
-
44. ) (canceled)
- 47. ) A method of treating a C5, C5a and/or C5b-9 mediated ocular disorder, the method comprising the step of administering an anti-C5 agent to a subject in need thereof in an amount sufficient to treat the ocular disorder.
-
50. ) (canceled)
- 51. ) A method of stabilizing a C5, C5a and/or C5b-9 mediated ocular neovascularization disorder comprising administering an anti-C5 agent to a subject in need thereof in an amount sufficient to stabilize the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.
-
53_-54. )-54) (canceled)
-
59_-62. )-62) (canceled)
- 63. ) A method of preventing a clinical C5, C5a and/or C5b-9 mediated ocular neovascularization disorder in a subject comprising administering an anti-C5 agent to a subject, the method comprising the step of administering the anti-C5 agent to the subject in an amount sufficient to prevent a clinical symptom of the C5, C5a and/or C5b-9 mediated ocular neovascularization disorder.
-
65_-66. )-66) (canceled)
Specification